On August 27, 2019, the seminar on Preclinical Research of Innovative Drugs hosted by Shanghai Medicilon Inc. was successfully held in Beijing. The seminar attracted more than 200 pharmaceutical R&D experts from 150 pharmaceutical companies around Beijing. The R&D Team of Medicilon shared a lot of relevant knowledge and case study experience of preclinical drug research and application process to the attendees, which provided reference and direction for preclinical research of innovative drugs.
The seminar was divided into two sessions. The first session was presided over by Professor Shuangqing Peng, VP and Head of the Preclinical Research Department. Professor Peng emphasized the importance of innovative drug research and pointed out that Medicilon has accumulated a 15-years of experience on innovative drug research and development.
Hereafter, Dr. Chunlin Chen, CEO of Medicilon, gave a speech during the seminar. Dr. Chen expressed that Medicilion witnessed the growth of new drug research and development in China. Dr. Chen also shared some topics regarding the preclinical evaluation and reporting experience of drugs required by CFDA and US FDA.
The second session was hosted by Dr. Feng Ren, VP of the Chemistry Services Department. Dr. Xingchu Gu, VP of Preclinical Research Department, and Dr. Xiancheng Zeng, Senior Director of the Department of Toxicology Research, introduced the preclinical drug research, pharmacokinetics and toxicology tests with the current hotspot, antibody-drug conjugated (ADC). Dr. Zheyi Hu, Senior Director of Pharmacology Department, introduced the cancer treatment and preclinical tumor efficacy models for the content of the efficacy evaluation system.